Prof. Heerspink: DAPA-CKD and Use of Dapagliflozin

Podcast

A podcast featuring the presenter of DAPA-CKD discussing results of the trial and how they inform use of dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes.

In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink, PhD, on dapagliflozin as a treatment in patients with chronic kidney disease.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology Congress 2020. The trial examined the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
© 2024 MJH Life Sciences

All rights reserved.